Insider · CIK 0001941467
Nicholas Hollmeyer Lynton
Files at CDLX (Cardlytics, Inc.). First filing Jan 6, 2025, latest Apr 2, 2026.
Nicholas Hollmeyer Lynton files SEC Form 4 as officer at CDLX (Cardlytics, Inc.). Since Jan 6, 2025, Nicholas Hollmeyer Lynton has reported 0 open-market buys worth $0 and 8 open-market sells worth $116k, the latest filed on Apr 2, 2026.
A track record needs three past buys with six months of prices behind them; Nicholas Hollmeyer Lynton has 0, so none is measured yet.
The newest scored trade: sold $40k of CDLX on Apr 1, 2026, filed Apr 2, 2026, scored 19 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $47k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CDLX: Cardlytics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Cardlytics, Inc. | $40k 40,296 shares | -19% | +49% from low-68% from high | |
| 15Weak | Cardlytics, Inc. | $7,316 6,253 shares | -5% | +39% from low-68% from high | |
| 15Weak | Cardlytics, Inc. | $14k 6,098 shares | -5% | +166% from low-55% from high | |
| 15Weak | Cardlytics, Inc. | $9,396 5,271 shares | -5% | +47% from low-65% from high | |
| 0Weak | CDLXsell Cardlytics, Inc. | $458 303 shares | -0% | +26% from low-70% from high | |
| 15Weak | Cardlytics, Inc. | $10k 5,754 shares | -5% | +1% from low-65% from high | |
| 8Weak | Cardlytics, Inc. | $11k 3,377 shares | -3% | - | |
| 15Weak | Cardlytics, Inc. | $24k 6,464 shares | -7% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 1, 2026 | CDLX Cardlytics, Inc. | 40,296 0.07% of outstanding | $40k | Apr 1, 2026 | $7,318 |
| Jan 5, 2026 | CDLX Cardlytics, Inc. | 6,253 0.01% of outstanding | $7,318 | Jan 5, 2026 | none |
| Oct 2, 2025 | CDLX Cardlytics, Inc. | 6,098 0.01% of outstanding | $14k | Oct 2, 2025 | $9,396 |
| Jul 2, 2025 | CDLX Cardlytics, Inc. | 5,271 0.01% of outstanding | $9,396 | Jul 2, 2025 | $11k |
| Apr 22, 2025 | CDLX Cardlytics, Inc. | 303 0.00% of outstanding | $458 | Apr 22, 2025 | $21k |
| Apr 2, 2025 | CDLX Cardlytics, Inc. | 5,754 0.01% of outstanding | $10k | Apr 2, 2025 | $34k |
| Jan 30, 2025 | CDLX Cardlytics, Inc. | 3,377 0.01% of outstanding | $11k | Jan 30, 2025 | $24k |
| Jan 3, 2025 | CDLX Cardlytics, Inc. | 6,464 0.01% of outstanding | $24k | Jan 3, 2025 | none |
Transactions
The newest 50 of 58 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +582 | - | - | 123,444 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +1,578 | - | - | 125,022 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +10,630 | - | - | 135,652 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +12,500 | - | - | 148,152 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +60,000 | - | - | 208,152 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -40,296 | $0.99 | $40k | 167,856 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -582 | $0.00 | $0 | 0 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,578 | $0.00 | $0 | 1,578 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -10,630 | $0.00 | $0 | 0 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -12,500 | $0.00 | $0 | 12,500 | Apr 2, 2026 |
| Apr 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -60,000 | $0.00 | $0 | 60,000 | Apr 2, 2026 |
| Feb 18, 2026 | CDLX Cardlytics, Inc. | AGrant or award Restricted Stock Unitderivative | +220,000 | $0.00 | $0 | 220,000 | Feb 20, 2026 |
| Jan 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +581 | - | - | 116,908 | Jan 5, 2026 |
| Jan 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +1,578 | - | - | 118,486 | Jan 5, 2026 |
| Jan 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +10,629 | - | - | 129,115 | Jan 5, 2026 |
| Jan 5, 2026 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -6,253 | $1.17 | $7,316 | 122,862 | Jan 5, 2026 |
| Jan 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -581 | $0.00 | $0 | 582 | Jan 5, 2026 |
| Jan 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,578 | $0.00 | $0 | 3,156 | Jan 5, 2026 |
| Jan 1, 2026 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -10,629 | $0.00 | $0 | 10,630 | Jan 5, 2026 |
| Oct 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +10,630 | - | - | 120,266 | Oct 2, 2025 |
| Oct 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +581 | - | - | 120,847 | Oct 2, 2025 |
| Oct 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +1,578 | - | - | 122,425 | Oct 2, 2025 |
| Oct 2, 2025 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -6,098 | $2.27 | $14k | 116,327 | Oct 2, 2025 |
| Oct 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -10,630 | $0.00 | $0 | 21,259 | Oct 2, 2025 |
| Oct 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -581 | $0.00 | $0 | 1,163 | Oct 2, 2025 |
| Oct 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,578 | $0.00 | $0 | 4,734 | Oct 2, 2025 |
| Jul 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +10,629 | - | - | 112,748 | Jul 2, 2025 |
| Jul 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +581 | - | - | 113,329 | Jul 2, 2025 |
| Jul 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +1,578 | - | - | 114,907 | Jul 2, 2025 |
| Jul 2, 2025 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -5,271 | $1.78 | $9,396 | 109,636 | Jul 2, 2025 |
| Jul 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -10,629 | $0.00 | $0 | 31,889 | Jul 2, 2025 |
| Jul 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -581 | $0.00 | $0 | 1,744 | Jul 2, 2025 |
| Jul 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,578 | $0.00 | $0 | 6,312 | Jul 2, 2025 |
| Jun 23, 2025 | CDLX Cardlytics, Inc. | AGrant or award Restricted Stock Unitsderivative | +25,000 | $0.00 | $0 | 25,000 | Jun 25, 2025 |
| Jun 23, 2025 | CDLX Cardlytics, Inc. | AGrant or award Performance Stock Unitderivative | +9,375 | $0.00 | $0 | 9,375 | Jun 25, 2025 |
| Apr 20, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +682 | - | - | 102,422 | Apr 22, 2025 |
| Apr 22, 2025 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -303 | $1.51 | $458 | 102,119 | Apr 22, 2025 |
| Apr 20, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -682 | $0.00 | $0 | 0 | Apr 22, 2025 |
| Apr 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +10,629 | - | - | 105,335 | Apr 3, 2025 |
| Apr 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +581 | - | - | 105,916 | Apr 3, 2025 |
| Apr 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +1,578 | - | - | 107,494 | Apr 3, 2025 |
| Apr 2, 2025 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -5,754 | $1.81 | $10k | 101,740 | Apr 3, 2025 |
| Apr 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -10,629 | $0.00 | $0 | 42,518 | Apr 3, 2025 |
| Apr 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitderivative | -581 | $0.00 | $0 | 2,325 | Apr 3, 2025 |
| Apr 1, 2025 | CDLX Cardlytics, Inc. | MOption exercise Restricted Stock Unitsderivative | -1,578 | $0.00 | $0 | 7,890 | Apr 3, 2025 |
| Mar 19, 2025 | CDLX Cardlytics, Inc. | AGrant or award Performance Stock Unitderivative | +45,000 | $0.00 | $0 | 0 | Mar 21, 2025 |
| Mar 19, 2025 | CDLX Cardlytics, Inc. | AGrant or award Restricted Stock Unitderivative | +120,000 | $0.00 | $0 | 0 | Mar 21, 2025 |
| Jan 29, 2025 | CDLX Cardlytics, Inc. | MOption exercise Common Stock | +6,312 | - | - | 98,083 | Jan 30, 2025 |
| Jan 30, 2025 | CDLX Cardlytics, Inc. | SOpen-market sale Common Stock | -3,377 | $3.19 | $11k | 94,706 | Jan 30, 2025 |
| Jan 29, 2025 | CDLX Cardlytics, Inc. | AGrant or award Performance Stock Unitderivative | +6,312 | $0.00 | $0 | 6,312 | Jan 30, 2025 |
Questions about Nicholas Hollmeyer Lynton
Answered from the filings on this page, as of the latest one.
Is Nicholas Hollmeyer Lynton buying or selling?
In the last 12 months Nicholas Hollmeyer Lynton reported 0 open-market buys worth $0 and 2 open-market sells worth $47k on SEC Form 4; the latest was sold $40k of CDLX on Apr 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Nicholas Hollmeyer Lynton's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nicholas Hollmeyer Lynton has 0.
Where does Nicholas Hollmeyer Lynton file Form 4?
Nicholas Hollmeyer Lynton has filed Form 4 at CDLX (Cardlytics, Inc.) as Chief Legal & Privacy Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.